Quest Diagnostics (DGX) to Release Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) is anticipated to post its quarterly earnings results before the market opens on Tuesday, April 22nd. Analysts expect Quest Diagnostics to announce earnings of $2.18 per share and revenue of $2.63 billion for the quarter. Quest Diagnostics has set its FY 2025 guidance at 9.550-9.800 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Trading Up 2.5 %

Shares of DGX stock opened at $168.05 on Tuesday. Quest Diagnostics has a fifty-two week low of $125.42 and a fifty-two week high of $178.87. The company has a quick ratio of 1.02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82. The business has a fifty day simple moving average of $168.57 and a 200-day simple moving average of $160.05. The stock has a market cap of $18.65 billion, a P/E ratio of 21.85, a P/E/G ratio of 2.16 and a beta of 0.78.

Quest Diagnostics Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 21st. Shareholders of record on Monday, April 7th will be issued a dividend of $0.80 per share. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.75. This represents a $3.20 annualized dividend and a yield of 1.90%. The ex-dividend date is Monday, April 7th. Quest Diagnostics’s dividend payout ratio (DPR) is 41.61%.

Insiders Place Their Bets

In other news, CEO J. E. Davis sold 39,191 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $168.46, for a total value of $6,602,115.86. Following the transaction, the chief executive officer now directly owns 127,623 shares in the company, valued at $21,499,370.58. This trade represents a 23.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $164.30, for a total value of $66,212.90. Following the sale, the senior vice president now owns 4,624 shares of the company’s stock, valued at $759,723.20. The trade was a 8.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,903 shares of company stock valued at $9,460,221 over the last quarter. Company insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

A hedge fund recently bought a new stake in Quest Diagnostics stock. Brighton Jones LLC purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,144 shares of the medical research company’s stock, valued at approximately $323,000. 88.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DGX shares. Truist Financial increased their price target on shares of Quest Diagnostics from $172.00 to $182.00 and gave the company a “hold” rating in a research report on Friday, January 31st. Piper Sandler reissued a “neutral” rating and set a $180.00 price target (up previously from $165.00) on shares of Quest Diagnostics in a research report on Monday, February 3rd. UBS Group upped their price objective on Quest Diagnostics from $166.00 to $170.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Morgan Stanley upgraded Quest Diagnostics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $145.00 to $172.00 in a research report on Tuesday, December 17th. Finally, Redburn Partners set a $195.00 target price on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.